Together with this, according to a 6-year follow-up study on a new medication administered to newly diagnosed T2DM patients, those receiving triple treatment (metformin, exenatide, and pioglitazone) had less hepatic fibrosis and steatosis than those receiving stepwise conventional therapy (metformin → glipizide → glargine insulin)24. The gene discussed is INS; the disease is Hepatic fibrosis.